Current Trends in the Radiodiagnosis of Hodgkin’s Lymphoma in Children

The main techniques used for the primary staging and evaluation of treatment response in children with Hodgkin's Lymphoma (HL) are contrast-enhanced computed tomography (CECT) and 18F-fl.uorodeoxygLucose positron emission tomography combined with computed tomography (18F-FDG PET/CT). Both techniques have a high sensitivity and specificity. Despite this, a single diagnostic protocol has not yet been developed for children with Hodgkin's Lymphoma. The simultaneous use of the two methods is not aLways appropriate at each treatment stage. The unreasonabLe consecutive performance of CECT and 18F-FDG PET/CT in children with HL increases the cumulative radiation dose for a child and the consumption of equipment resources. This article describes in detail the main advantages and disadvantages of CECT and 18F-FDG PET/CT at all stages of management of children with HL, as well as various approaches for current diagnostic algorithms in the primary staging of HL in children and in the evaluation of treatment efficiency.

Literature was sought using the following databases: Pubmed, Uptodate, ClinikalKey, CyberLen-inka, and Russian Science Citation Index (RSCI).

1. Самочатова Е.В. Лимфома Ходжкина. В кн.: Педиатрия: Национальное руководство. М.: ГЭОТАР-медиа; 2009: 968-73. [Samochatova E.V. Hodgkin’s lymphoma. In: Pediatrics: National Guidelines. Moscow: GEOTAR-media; 2009: 968-73 (in Russ.)].

2. Brousse N., Vasiliu V., Michon J., Canioni D. Pediatric non-Hodgkin lymphomas (2004). Annales de pathologie. 2004; 24: 574-86. DOI: AP-12-2004-24-6-0242-6498-101019-200500260

3. Mauz-Korholz C., Kelly K.M. Pediatric Hodgkin Lymphoma. Clinical Oncology. 2015; 33: 2975-85. DOI: 10.1200/JCO.2014.59.4853

4. Hutchings M., Loft A., Hansen M., L. Pedersen L.M., Berthelsen A.K., Keiding S. Position emission tomography with or without computed tomography in the primary staging of Hodgkin’s lymphoma. Haematolo-gica. 2006; 91: 482-9. http://www.haematologica.org/content/91/4/482.long (дата обращения: 01.10.2018).

5. Ansell M.S., Stephen M. Hodgkin lymphoma-diagnosis and treatment. Mayo Clinic Proceedings. 2015; 90(11): 1574-83. DOI: 10.1016/j.mayocp.2015.07.005 (дата обращения: 01.10.2018).

6. Howard J. Treatment of Pediatric Hodgkin Lymphoma. In: Howard J., Melissa M., Michael P. Pediatric Lymphomas. Springer; 2015: 67-9.

7. Ferrari C., Asabella N.A., Merenda N., Altini C., Fanelli M., Muggeo P. et al. Pediatric Hodgkin Lymphoma Predictive value of interim 18F-FDG PET/CT in therapy response assessment. Medicine (Baltimore). 2017; 96(5): 5973. DOI: 10.1097/MD.0000000000005973

8. Vock P. CT radiation exposure in children: Consequences of the American discussion for Europe. Radiologe. 2002; 42: 697-702. DOI: 10.1007/s00117-002-0812-4

9. KrilleL, Zeeb H., Jahnen A., Mildenberger P., Schneider K., Weisser G. et al. Computed tomographies and cancer risk in children: a literature overview of CT practices, risk estimations and an epidemiologic cohort study proposal. Radiation and Enviromental Biophysics. 2012; 51: 103-11. DOI: 10.1007/s00411-012-0405-1

10. Voss S.D., Chen L., Constine L.S., Chauvenet A., Fitzgerald T.J., Kaste S.C. et al. Surveillance Computed Tomography Imaging and Detection of Relapse in Intermediate- and Advanced-Stage Pediatric Hodgkin’s Lymphoma: A Report From the Children’s Oncology Group. J Clin Oncol. 2012; 30: 2635-40. DOI: 10.1200/JCO.2011.40.7841

11. Vallin C., Blouin P., Venel Y., Maurin L., Srinelli D. The use of computed tomography and nuclear medicine examinations in paediatric oncology: An analysis of practice in a university hospital. Diagnostic and Interventional Imaging. 2014; 95: 411-9. DOI: 10.1016/j.diii.2013.12.016

12. Thomas K.E., Wang B. Age-specific effective doses for pediatric MSCT examinations at a large children’s hospital using DLP conversion coefficients: a simple estimation method. Pediatr Radiol. 2008; 38: 645-56. DOI: 10.1007/s00247-008-0794-0

13. Ahmed B.A., Bairbre L., Connolly B.L., Puneet Sh., Chong A.L., Thomas E. et al. Cumulative Effective Doses from Radiologic Procedures for Pediatric Oncology Patients. Pediatrics. 2010; 126(4): 851-8. DOI: 10.1542/peds.2009-2675

14. Isik E.G., Kuymcu S., Kebudi R., Sanli Y., Karakas Z., Cakir F.B. et al. Prediction of outcome in pediatric Hodgkin lymphoma based on interpretation of 18FDG-PET/CT according to ASUVmax, Deauville 5-point scale and IHP criteria. Ann Nucl Med. 2017; 31(9): 660-8. DOI: 10.1007/s12149-017-1196-x

15. Tian L., Cai P.O., Cui C.Y., Mo Y.X., Gong X., Fan W. Reactive thymic hyperplasia following chemotherapy for children with lymphoma: computed tomography may be able to provide valuable information to avoid over-treatment. Eur J CardiothoracSurg. 2015; 47: 883-9. DOI: 10.1093/ejcts/ezu303

16. Nasseri F., Eftekhari F. Clinical and radiologic review of the normal and abnormal thymus: pearls and pitfalls. Radiographics. 2010; 30(2): 413-28. DOI: 10.1148/rg.302095131

17. Nogami M., Nakamoto Y., Sakomoto S., Fukushima K., Okada T., Saga T. Diagnostic performance of CT, PET, side-by-side, and fused image interpretations for restaging of non-Hodgkin lymphoma. Ann Nucl Med. 2007; 21: 189-96. DOI: 10.1007/s12149-007-0015-1

18. Kwee T.C., Kwee R.M. Imaging in staging of malignant lymphoma: a systematic review. Blood. 2008; 111(2): 505-15. DOI: 10.1182/blood-2007-07-101899

19. Miglioretti D.L., Johnson E., Williams A., Pediatric Computed Tomography and Associated Radiation Exposure and Estimated Cancer Risk. JAMA pediatrics. 2013; 167(8): 700-7. DOI: 10.1001/jamapediatrics.2013.311

20. Cheson B.D., Fisher R.I., Barrington S.F., Cavalli F., Schwartz L.H., Zucca E. et al. Recommendations forini-tial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification. J Clin Oncol. 2014; 32(27): 3059-68. DOI: 10.1200/ЮЭ.2013.54.8800

21. Rohren M.E., Turkington T.G., Coleman E. Clinical Applications of PET in oncology. Radiology RSNA. 2011; 2: 231-8. DOI: 10.1148/radiol.2312021185 (дата обращения: 01.10.2018).

22. Belohlavek O., Bombardieri E., Hicks R., Sasaki Y. et al. A guide to clinical PET in oncology-improving clinical PET in oncology, 2008. http://www-pub.iaea.org/MTCD/Publications/PDF/te_1605_web.pdf

23. Weiler-Sagie M., Bushelev O., Epelbaum R., Dann E.J., Haim N., Avivi I. et al. (18)F-FDG avidity in lymphoma readdressed: A study of 766 patients. J Nucl Med. 2010; 51: 25-30. DOI 10.2967/jnumed.109.067892

24. Israel O., Keidar Z., Bar-Shalom R. Positron emission tomography in the evaluation of lymphoma. Semin Nucl Med. 2004; 3: 166-79. DOI: 10.1053/j.semnuc-lmed.2004.03.002

25. Hamersvelt H.P., Kwee T.C., Fijnheer R., Beek F.J., Klerk J.M. Canfull-dosecontrast-enhansed CT beomitted from an FDG-PET/CT staging examination new lydiagnosed FDG-avid lymphoma? J Comput Assist Tomogl. 2014; 38: 620-5. DOI: 10.1097/RCT.0000000000000067

26. Niamh M.L., Clare S.S. Causes and imaging features of false positives and false negatives on 18F-PET/CT in oncologic imaging. Insights Imaging. 2011; 2: 679-98. DOI: 10.1007/s13244-010-0062-3

27. Ouintanilla-Martinez L., Sander B., Chan J.K., Xerri L., Ott G., Campo E. et al. Indolent lymphomas in the pediatric population: follicular lymphoma, IRF4/MUM1+ lymphoma, nodal marginal zone lymphoma and chronic lymphocytic leukemia. Virchows Archiv. 2016; 141-57. DOI: 10.1007/s00428-015-1855-z

28. Hernandez-Pampaloni M., Takalkar A., Jian O.Yu., Zhuang H., Alavi A. F-18 FDG-PET imaging and correlation with CT in staging and follow-up of pediatric lymphomas. Pediatr Radiol. 2006; 36: 524-31. DOI: 10.1007/s00247-006-0152-z

29. Sue C.K. PET-CT in children: where is it appropriate? Pediatr Radiol. 2011; 41: 509-13. DOI: 10.1007/s00247-011-2096-1

30. Stauss J., Franzius C., Pfluger T., Biassoni L., Begent J., Kluge R. et al. Guidelines for 18F-FDG PET and PET-CT imaging in paediatric oncology. Eur J Nucl Med Mol Imaging. 2008; 35: 1581-8. DOI: 10.1007/s00259-008-0826-x

31. Nagpal P., Akl M.R., Ayoub N.M., Tomiyama T., Cousins T., Caroll N. et al. Pediatric Hodgkin Lymphoma - Biomarkers, Drugs, and Clinical Trials for Translational Science and Medicine. Oncotarget. 2016; 7: 67551-73. DOI: 10.18632/oncotarget.11509